Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Equity Average (2016 - 2017)

Tenax Therapeutics' Equity Average history spans 5 years, with the latest figure at $10.7 million for Q3 2017.

  • For Q3 2017, Equity Average fell 78.04% year-over-year to $10.7 million; the TTM value through Sep 2017 reached $10.7 million, down 78.04%, while the annual FY2016 figure was $43.8 million, N/A changed from the prior year.
  • Equity Average for Q3 2017 was $10.7 million at Tenax Therapeutics, down from $12.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $48.8 million in Q3 2016 and bottomed at -$829302.0 in Q1 2013.
  • The 3-year median for Equity Average is $14.2 million (2017), against an average of $19.8 million.
  • The largest YoY upside for Equity Average was 78.04% in 2017 against a maximum downside of 78.04% in 2017.
  • A 3-year view of Equity Average shows it stood at -$829302.0 in 2013, then surged by 3948.64% to $31.9 million in 2016, then plummeted by 66.43% to $10.7 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Equity Average are $10.7 million (Q3 2017), $12.7 million (Q2 2017), and $15.6 million (Q1 2017).